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Abstract
Background: Patterns of care for acute myocardial infarction (AMI) strongly depend on the
availability of on-site cardiac catheterization facilities. Although the management found at hospitals
without on-site catheterization does not lead to increased mortality, little it known about its impact
on resource utilization and non-fatal outcomes.
Methods: We identified all patients (n = 35,289) admitted with a first AMI in the province of
Quebec between January 1, 1996 and March 31, 1999 using population-based administrative
databases. Medical resource utilization and non-fatal and fatal outcomes were compared among
patients admitted to hospitals with and without on-site cardiac catheterization facilities.
Results:  Cardiac catheterization and PCI were more frequently performed among patients
admitted to hospitals with catheterization facilities. However, non-invasive procedures were not
used more frequently at hospitals without catheterization facilities. To the contrary,
echocardiography [odds ratio (OR), 2.04; 95% confidence interval (CI), 1.93–2.16] and multi-gated
acquisition imaging (OR, 1.24; 95% CI, 1.17–1.32) were used more frequently at hospitals with
catheterization, and exercise treadmill testing (OR, 1.02; 95% CI, 0.91–1.15) and Sestamibi/
Thallium imaging (OR, 0.93; 95% CI, 0.88–0.98) were used similarly at hospitals with and without
catheterization. Use of anti-ischemic medications and frequency of emergency room and physician
visits, were similar at both types of institutions. Readmission rates for AMI-related cardiac
complications and mortality were also similar [adjusted hazard ratio, recurrent AMI: 1.02, 95% CI,
0.89–1.16; congestive heart failure: 1.02; 95% CI, 0.90–1.15; unstable angina: 0.93; 95% CI, 0.85–
1.02; mortality: 0.99; 95% CI, 0.93–1.05)].
Conclusion: Although on-site availability of cardiac catheterization facilities is associated with
greater use of invasive cardiac procedures, non-availability of catheterization did not translate into
a higher use of non-invasive tests or have an impact on the fatal and non-fatal outcomes available
for study in our administrative database.
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Background
Advances in pharmacological therapy and mechanical
revascularization have markedly contributed to improved
outcomes following acute myocardial infarction (AMI).
However, practice variations persist with respect to the use
of these treatment strategies. One factor known to contrib-
ute to this variation is the regionalization of facilities for
invasive cardiac procedures. Strong, positive associations
between the use of invasive cardiac procedures and the
presence of on-site cardiac catheterization facilities have
been established [1-9].
Several clinical trials and observational studies have sug-
gested that a more invasive approach to management of
AMI – as is found at hospitals with on-site cardiac cathe-
terization facilities – is not associated with improved sur-
vival for all patient subgroups [2-4,6,7,10-17]. Thus, it is
possible that the benefit of a universally applied invasive
approach may not be commensurate with its substantial
use of resources. However, it is also possible that there are
aspects of a more selectively invasive approach – as is
found at hospitals without on-site cardiac catheterization
– that drive resource utilization, such as the use of non-
invasive procedures after AMI.
We sought to determine how availability of on-site cardiac
catheterization facilities at the hospital of admission for
AMI might influence resource utilization, as well as fatal
and non-fatal outcomes after AMI. We hypothesized that
non-availability of cardiac catheterization facilities might
translate into a higher use of non-invasive cardiac proce-
dures, given the need to perform cardiac risk stratification.
We also hypothesized that a lower use of invasive cardiac
procedures might impact on the use of anti-ischemic med-
ications, emergency room and outpatient physician visits,
readmissions for AMI-related complications and mortal-
ity.
Methods
Study Population
A cohort of AMI patients was constructed from the univer-
sal hospital discharge summary database for the province
of Quebec, Canada. We identified all patients admitted
with a discharge diagnosis of AMI [International Classifi-
cation of Diseases (ICD), 9th revision code 410] between
January 1st 1996 and March 31st 1999 (n = 40,857). The
positive predictive value for coding an AMI for elderly
patients in the database has been evaluated to be 96%
(95% CI, 94–98) [18]. In order to increase comparability
and include patients based on only first episodes of AMI,
we excluded patients who had a previous diagnosis of
AMI between 1988 and 1995 (9.3%). Additional patients
were excluded if they were admitted to non-cardiac surgi-
cal units, or if the total length of stay (including transfers)
for their admission was less than three days, because AMI
is unlikely to be the primary diagnosis for such patients.
Following these exclusions, our study population con-
sisted of 35,289 patients (total exclusions were 13.6% of
the original cohort). This method to identify AMI patients
has been used extensively in Quebec [19], Ontario [20],
and the United States [21].
Using encrypted Quebec Medicare numbers, we further
linked the discharge summary database with the physi-
cian and drug claims database for the province of Quebec.
These databases contain information on all diagnostic
and therapeutic procedures in Quebec. They also contain
information on resource use, such as outpatient physician
visits and outpatient prescriptions filled. Due to the char-
acteristics of the Quebec health care and health insurance
systems, information on prescriptions was limited to
patients 65 years of age and older.
Mortality data were obtained by merging data from sev-
eral different sources: the hospital discharge summary
database, institutions that manage pensions, government
human resources and car insurance, and provincial death
certificates. The algorithm we created using these different
sources of information allowed us to determine the vital
status for close to 100% of the study patients. All patients
were followed from the date of their initial admission
until December 31, 1999.
Hospital Groups
Study patients were grouped based on whether their
admitting hospital had on-site cardiac catheterization
facilities. A total of 16 hospitals had on-site cardiac cathe-
terization facilities over the study period, and there were
no changes in availability of catheterization at each of
these hospitals over the study period. However, the
number of hospitals without cardiac catheterization facil-
ities changed over time, as there were some hospital clo-
sures between 1996 and 1999. Over these years, 100 to
116 hospitals were hospitals without cardiac catheteriza-
tion facilities. Patients were classified according to
whether or not they were initially admitted for AMI at
hospitals with or without cardiac catheterization facilities.
If a patient was initially admitted to a hospital without
catheterization, and then transferred to a hospital with
catheterization, the patient was "assigned" to the initial
hospital without catheterization only.
Medical Care Utilization
For each patient, we obtained data on all in- and outpa-
tient invasive and non-invasive cardiac procedures per-
formed during the follow-up period. The invasive
procedures studied were cardiac catheterization, percuta-
neous coronary intervention (PCI), and coronary artery
bypass graft surgery (CABG). The non-invasive procedures
studied were exercise treadmill testing, transthoracicBMC Health Services Research 2006, 6:148 http://www.biomedcentral.com/1472-6963/6/148
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echocardiography, and nuclear cardiac imaging [multi-
gated acquisition (MUGA), Thallium/Sestamibi]. We
examined cumulative incidence of all these procedures
during the initial hospital admission for AMI, as well as at
1 year following the date of the initial admission for AMI.
We also examined rates of primary PCI, which was
defined as receipt of PCI on the day of admission for AMI.
In addition, we determined the median waiting period
(time in days) between the date of the initial admission
and any invasive cardiac procedure received within 1 year.
We also obtained data on prescriptions for medications
with anti-ischemic properties, as well as frequency of
emergency room and physician visits. The anti-ischemic
medications studied were beta-blockers, nitrates and cal-
cium channel blockers. We measured the cumulative inci-
dence of prescriptions filled at 30 days post-discharge. We
also measured the cumulative incidence of anti-ischemic
combination therapy for the patients who were alive at 1
year post-discharge. Anti-ischemic combination therapy
was defined as prescription for one (monotherapy), two
(double therapy) or three (triple therapy) agents among
beta-blockers, nitrates, and calcium channel blockers at 1
year post-discharge.
The frequencies of emergency room and outpatient physi-
cian visits during the year following discharge were also
measured. All emergency room visits were included in
analyses, irrespective of the reason for consultation. Out-
patient physician visits included visits to internists, cardi-
ologists, and family physicians.
Readmissions and Mortality
Readmission rates for cardiac-specific diagnoses exam-
ined were recurrent AMI (ICD-9 code 410), unstable
angina (ICD-9 code 411, 413, 414) and congestive heart
failure (ICD-9 code 428). Specifically, we measured
cumulative incidence of readmission for these diagnoses
at 30 days and 1 year following the date of discharge. Con-
sistent with previous studies using similar administrative
databases [8], we excluded any elective readmissions for
invasive cardiac procedures.
Finally, cumulative incidence of mortality was measured
during the initial hospitalization and at 30 days and 1
year after admission.
Statistical Analysis
We compared demographic and clinical characteristics,
use of cardiac procedures and medications, frequency of
emergency room and physician visits, and readmission
and mortality rates for patients initially admitted for AMI
at hospitals with and without on-site cardiac catheteriza-
tion facilities. We then used multivariable Cox's propor-
tional hazards models to estimate the association between
admission at hospitals with and without cardiac catheter-
ization facilities and the study outcomes. Assumptions of
proportionality for the Cox models were verified for each
study outcome. The models adjusted for age at admission,
sex, the interaction between age at admission and sex, the
year of admission, co-morbid illnesses (diabetes mellitus,
chronic obstructive pulmonary disease, cerebrovascular
disease, malignancy, congestive heart failure, renal failure,
peripheral vascular disease), shock, specialty of the treat-
ing physician (cardiologist or not), university affiliation
of hospital of admission, and AMI patient volume of hos-
pital of admission (low, medium or high volume). The
study was approved by the institutional review board at
the McGill University, Montreal, Canada.
Results
Patient Characteristics
Among the 35,289 study patients, 9,355 (27%) were
admitted to hospitals with on-site cardiac catheterization
facilities. Patients admitted to both types of hospitals had
similar demographic and clinical characteristics, but dif-
ferent hospital characteristics (Table 1). For example,
patients admitted to hospitals with cardiac catheterization
facilities were more likely to be treated by cardiologists, to
be admitted to a university-affiliated hospital and a high-
volume (>100 AMI admissions/year) hospital. Finally,
median length of stay was shorter for patients admitted to
hospitals with cardiac catheterization facilities.
Invasive Cardiac Procedures
Invasive cardiac procedures were performed in a higher
proportion of patients admitted to hospitals with cardiac
catheterization facilities (Table 2). Catheterization was
used more frequently in-hospital [odds ratio (OR), 4.00;
95% confidence interval (CI), 3.78–4.24] and at 1 year
(OR, 1.76; 95% CI, 1.68–1.85). Similarly, PCI was used
more frequently in-hospital (OR, 6.20; 95% CI, 5.70–
6.74) and at 1 year (OR, 1.98; 95% CI, 1.86–2.09). Pri-
mary PCI (among patients with catheterization) was also
used more frequently (OR, 41.8; 95% CI, 32.2–54.3).
Rates of CABG were slightly higher for patients admitted
to hospitals with cardiac catheterization facilities in-hos-
pital (OR, 1.91; 95% CI, 1.48–2.45), but modestly lower
at 1 year (OR, 0.86; 95% CI, 0.78–0.94).
Waiting periods between admission and procedures were
shorter for patients admitted to hospitals with cardiac
catheterization facilities. However, for those patients who
required CABG following catheterization, there was no
difference in the waiting period from catheterization to
CABG in both types of hospitals.
Non-invasive Cardiac Procedures
Overall, non-invasive cardiac procedures were not used
more frequently at hospitals without on-site availabilityBMC Health Services Research 2006, 6:148 http://www.biomedcentral.com/1472-6963/6/148
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of cardiac catheterization facilities (Table 2). To the con-
trary, echocardiography was used more frequently in hos-
pitals with cardiac catheterization facilities in-hospital
(OR, 2.56; 95% CI, 2.43–2.69) and at 1 year (OR, 2.04;
95% CI, 1.93–2.16). Similarly, MUGA imaging was used
more frequently in-hospital (OR, 1.32; 95% CI, 1.22–
1.42) and at 1 year (OR, 1.24; 95% CI, 1.17–1.32). In con-
trast, exercise treadmill testing was used similarly in both
groups (OR at 1 year, 1.02; 95% CI, 0.91–1.15) and Sesta-
mibi/Thallium imaging was used only slightly less fre-
quently at hospitals with cardiac catheterization facilities
(OR at 1 year, 0.93; 95% CI, 0.88–0.98).
Anti-Ischemic Prescriptions, Emergency Room and 
Physician Visits
There were no significant differences in rates of prescrip-
tions for cardiac medications at 30 days post-discharge
between the two groups (Table 3). Refill rates for sublin-
gual nitrates were also comparable in both groups, as were
rates of prescription for anti-ischemic combination ther-
apy at 1 year (Table 3). Furthermore, the total number of
emergency room and physician visits was similar in both
groups at 1 year post-discharge.
Readmissions and Mortality
We found similar rates of readmission for recurrent AMI
and congestive heart failure at 30 days and 1 year post-dis-
charge in both groups [recurrent AMI and congestive heart
failure adjusted hazard ratio (HR), 1.02; 95% CI, 0.89–
1.16 and HR, 1.02; 95% CI, 0.90–1.1), respectively]
(Table 4). There was no difference in readmission rates for
unstable angina (HR, 0.93; 95% CI, 0.85–1.02).
Mortality rates were also similar for patients admitted to
hospitals with and without cardiac catheterization facili-
ties in-hospital (9% versus 10%), at 30 days (13% versus
14%), and 1 year (20% versus 21%). In addition, adjusted
rates were similar for the entire follow-up period
(adjusted HR, 0.99; 95% CI, 0.93–1.05) (Figure 1).
Finally, because mortality is very high in patients with
shock and there was a higher proportion of patients with
shock at hospitals with on-site catheterization, we per-
Table 1: Patient and hospital characteristics, according to availability of on-site cardiac catheterization facilities at the hospital of 
admission for acute myocardial infarction
Hospitals with Catheterization Facilities 
(n= 9,355)
Hospitals without Catheterization Facilities 
(n= 25,934)
Patient characteristic (%)
Median age, years (IQR) 67 (55–76) 67 (55–76)
Patients >65 years 56.2 56.3
Male 65.4 64.9
Hypertension 35.0 28.8
Diabetes mellitus 22.0 19.9
Dyslipidemia 20.9 17.8
Heart failure 21.7 22.1
Atrial fibrillation 9.9 8.7
Chronic obstructive pulmonary disease 12.2 15.2
Peripheral vascular disease 8.5 7.8
Cerebrovascular disease 6.8 6.4
Chronic renal failure 7.3 5.7
Acute renal failure 4.8 4.6
Shock 5.7 4.7
Malignancy 2.1 2.3
Hospital characteristic (%)
Median length of stay, days (IQR) 7 (5–12) 9 (6–14)
Treating physician specialty
Cardiology 92.4 28.9
Family medicine 2.8 57.7
Internal medicine 2.3 12.4
University-affiliation 86.9 33.6
AMI patient volume
< 50 cases AMI/year 0 1.2
50–100 cases AMI/year 0 17.2
> 100 cases AMI/year 100.0 81.6
IQR denotes interquartile range, AMI denotes acute myocardial infarction.BMC Health Services Research 2006, 6:148 http://www.biomedcentral.com/1472-6963/6/148
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formed a model that excluded patients with shock and
failed to find a mortality difference (adjusted HR, 1.0;
95% CI, 0.94–1.07).
In univariate analysis, the effect of physicians specialty,
hospital teaching status and volume appeared to also
greatly affect the various outcomes that were measures
(Table 4). However, the effect of on-site catheterization
availability remained the same after addition of these var-
iables to our multivariate models. The relationship
between on-site catheterization and mortality and cardiac
readmissions is thus unexplained by these other variables.
However, in multivariate analysis, cardiologists appears to
be associated with better outcomes independent of being
admitted to a hospital with on-site catheterization and, in
particular, with fewer readmissions for unstable angina
[adjusted HR, recurrent AMI: 0.97; 95% CI, 0.86–1.08;
congestive heart failure: 0.92; 95% CI, 0.83–1.03; unsta-
ble angina: 0.90; 95% CI, 0.83–0.98; mortality: 0.93; 95%
CI, 0.88–0.98].
Discussion
Lack of availability of on-site cardiac catheterization facil-
ities did not result in an increased use of non-invasive test-
ing for risk stratification following AMI. In contrast,
despite a higher rate of use of in-hospital catheterization
(and presumably left ventriculography), ventricular
assessment via echocardiography and MUGA imaging was
used more frequently for patients admitted at hospitals
with catheterization facilities. Lower use and longer wait-
ing times for invasive cardiac procedures at hospitals with-
out catheterization facilities did not result in worse
clinical outcomes. Use of anti-ischemic medications, fre-
quency of emergency room and outpatient physician vis-
its, and rates of readmission for AMI-related cardiac
complications and mortality were unaffected by catheter-
ization availability.
The association between availability and use of on-site
cardiac catheterization facilities has been well docu-
mented [2,3]. Furthermore, the management strategy of
routine cardiac catheterization following AMI has been
shown not to impact on mortality, but few studies have
assessed the impact of this strategy on outcomes such as
non-fatal outcomes and utilization of medical resources.
A reduction in readmissions for unstable angina was
shown in the Thrombolysis In Myocardial Infarction
(TIMI) III-B trial, thus slightly favoring the "early inva-
Table 2: Cumulative incidence of invasive and non-invasive cardiac procedures
Hospitals with Catheterization Facilities 
(n = 9,355)
Hospitals without Catheterization Facilities 
(n = 25,934)
Non-invasive procedures (%)
Exercise treadmill test *
In-hospital 27.2 24.0
1 year 48.2 47.5
Echocardiogram
In-hospital 66.7 44.0
1 year 76.2 61.0
MUGA scan
In-hospital 11.0 8.6
1 year 23.9 20.1
Thallium/Sestamibi scan
In-hospital 8.3 6.0
1 year 23.8 25.2
Invasive procedures (%)
Catheterization
In-hospital 35.1 11.9
1 year 51.2 37.3
PCI
Primary PCI 9.0 0.2
In-hospital 18.5 3.5
1 year 28.2 16.6
CABG
In-hospital 1.1 0.6
1 year 8.2 9.4
MUGA denotes multi-gated acquisition, PCI denotes percutaneous coronary intervention, CABG denotes coronary artery bypass graft surgery.
*Data available only for patients admitted from June 1, 1998–1999 (n = 8,741).BMC Health Services Research 2006, 6:148 http://www.biomedcentral.com/1472-6963/6/148
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Table 3: Cardiac prescriptions, physicians and emergency room visits post-discharge after acute myocardial infarction
Hospitals with Catheterization Facilities 
(n = 4,116)
Hospitals without Catheterization 
Facilities (n = 11,190)
Medication class* (%)
Aspirin 65.4 64.2
Beta-blockers 57.7 52.6
ACE inhibitors 45.2 44.0
Nitrates (any form) 72.7 73.0
Calcium channel blockers 27.6 28.1
Lipid-lowering agents 24.9 20.8
Anti-ischemic combination therapy at 1 year† (%)
Monotherapy 38.8 41.6
Double therapy 27.3 27.9
Triple therapy 7.8 7.2
Refills for sublingual nitrates at 1 year (%) 31.4 28.7
Emergency room visits at 1 year (%)
0 visits 43.3 43.3
1–3 visits 41.4 41.3
≤4 visits 15.4 15.4
Physician visits at 1 year (%)
0–3 visits 22.3 18.9
4–8 visits 38.5 39.7
≤9 visits 39.2 41.4
ACE denotes angiotensin-converting enzyme.
* For patients ≤65 years of age only; † Anti-ischemic combination therapy was defined as prescription for one (monotherapy), two (double therapy) 
or three (triple therapy) agents among beta-blockers, nitrates, and calcium channel blockers at six months post-discharge (for patients ≤65 years of 
age only, n = 15,306).
Table 4: Effect of catheterization availability, physician specialty, university affiliation and volume on fatal and non-fatal outcome
Hazard Ratios and 95% Confidence Intervals
Catheterization 
Availability
Physician Specialty* University Affiliation Volume >= 150
Congestive Heart 
Failure
Unadjusted 1.01 (0.92 – 1.12) 0.85 (0.78 – 0.92) 1.03 (0.94 – 1.12) 0.97 (0.88 – 1.06)
Adjusted 1.02 (0.90 – 1.15) 0.92 (0.83 – 1.03) 1.07 (0.96 – 1.19) 0.94 (0.85 – 1.05)
Unstable Angina
Unadjusted 0.81 (0.76 – 0.87) 0.82 (0.77 – 0.87) 0.91 (0.86 – 0.97) 0.758 (0.71 – 0.81)
Adjusted 0.93 (0.85 – 1.02) 0.90 (0.83 – 0.98) 1.11 (1.03 – 1.19) 0.80 (0.74 – 0.86)
Recurrent AMI
Unadjusted 0.97 (0.87 – 1.07) 0.90 (0.83 – 0.99) 0.92 (0.84 – 1.01) 0.93 (0.84 – 1.03)
Adjusted 1.02 (0.89 – 1.16) 0.97 (0.86 – 1.08) 0.92 (0.83 – 1.03) 0.95 (0.85 – 1.06)
Mortality
Unadjusted 0.98 (0.94 – 1.03) 0.84 (0.81 – 0.88) 1.02 (0.98 – 1.06) 1.05 (1.00 – 1.10)
Adjusted 0.99 (0.93 – 1.05) 0.93 (0.88 – 0.98) 1.02 (0.97 – 1.07) 1.08 (1.03 – 1.14)
* Cardiologists compared to internists or family physicians.
Note: The adjusted relative risks need to be interpreted with caution because variables are highly correlated.BMC Health Services Research 2006, 6:148 http://www.biomedcentral.com/1472-6963/6/148
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sive" approach [15]. More recently, the Treat Angina with
Aggrastat and Determine Cost of Therapy with an Invasive
or Conservative Strategy-Thrombolysis In Myocardial Inf-
arction 18 (TACTICS-TIMI 18) investigators reported a
lower incidence of major cardiac events with the use of an
"early invasive" strategy combined with glycoprotein IIb/
IIIa inhibition [22]. Whereas the TIMI-IIIB and TACTICS
trials prospectively examined the incidence of cardiac
events following unstable angina and AMI, few investiga-
tors have used large administrative databases to examine
non-fatal outcomes and resource utilization with a popu-
lation-based approach. Our study extends these previous
studies by providing new information, at the population
level, for a large number of patients from a recent cohort.
This type of analysis is complementary to that of the clin-
ical trials, as it is relevant to the "real world" care of
patients in several jurisdictions where the routine applica-
tion of the invasive approach is not feasible. However,
given the overall relatively infrequent use of the invasive
approach in both study groups, this study cannot provide
a valid comparison of a routine invasive versus non-inva-
sive approach. Instead, it provides evidence that certain
outcomes are similar for patients treated at hospitals with
more versus less selective use of invasive cardiac proce-
dures, albeit at an overall still highly selective level. The
overall equivalence for other important endpoints, such
as outpatient burden of angina and heart failure symp-
toms, remains indeterminate.
Only one other study has recently used administrative
data to examine such a hypothesis [8]. Alter et al. found
that the non-fatal composite 5-year event rate was lower
when patients were admitted to hospitals with cardiac
catheterization facilities from 1992 to 1993. Unlike Alter
et al., we did not find an effect of availability of cardiac
catheterization facilities on rates of readmissions for
unstable angina. However, only 11% of patients in the
study by Alter et al. were initially admitted to hospitals
with cardiac catheterization facilities, suggesting that
lower readmission rates for angina may have been related
to elective admissions for invasive cardiac procedures.
Our results regarding cardiac readmissions reflect a more
recent trend of practice.
In order to identify the interplay between physician spe-
cialty, university affiliation, volume of AMI admissions
and on-site availability of cardiac catheterization facilities,
we included all these variables in our multivariate models.
There appears to be little confounding bias by physician
specialty, hospital teaching status and hospital volume of
AMI admissions. We could not identify any apparent ben-
efit of being treated at hospitals with cardiac catheteriza-
tion facilities, despite the more prevalent use of invasive
cardiac procedures, the shorter waiting periods for revas-
cularization, the greater proportion of patients treated by
cardiologists, university-affiliations, and the higher vol-
ume of AMI admissions. However, our multivariate
regression estimates should be interpreted with caution
due to their high correlation with availability of on-site
cardiac catheterization.
Our study presented the following limitations. First, while
we adjusted for several important patient-, physician- and
hospital-related characteristics in our multivariate analy-
ses, our administrative databases do not contain informa-
tion on in-hospital pharmacological treatment including
thrombolytic therapy or detailed clinical characteristics
that could confound our analyses. However, the similari-
ties in available clinical characteristics across the two
groups provide a good indication that more detailed clin-
ical characteristics would also be similar. Findings from a
previous study using detailed chart review data support
this claim. Second, it was difficult to assess the role of the
treating physician and the teaching status and volume of
the admitting hospital in relationship with catheteriza-
tion laboratory availability because these variables are
highly correlated. The difficulty to abstract collinear vari-
ables in such analyses represents an important challenge
in this field. Finally, there is the possibility for some mis-
classification bias in our databases. For example, a
readmission diagnosis of unstable angina may actually
reflect an elective admission for pre-planned cardiac cath-
eterization. As in previous studies, we excluded all
readmissions where catheterization was performed on the
same or next day following admission. In fact, few
patients were excluded under this criterion; we repeated
analyses with and without these exclusions and found
comparable readmission rates.
Probability of survival among patients with acute myocardial  infarction admitted at sites with and without cardiac cathe- terization facilities Figure 1
Probability of survival among patients with acute myocardial 
infarction admitted at sites with and without cardiac cathe-
terization facilities.
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Conclusion
In conclusion, the lower use of invasive cardiac proce-
dures at hospitals without on-site catheterization did not
translate into a higher use of non-invasive tests. Further-
more, use of anti-ischemic cardiac medications, emer-
gency room visits, outpatient physician visits,
readmissions for AMI-related complications and mortal-
ity were similar at each type of hospital.
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